Literature DB >> 28089760

Enhanced Long-Term Brain Magnetic Resonance Imaging Evaluation of Children with Sickle Cell Disease after Hematopoietic Cell Transplantation.

Nancy S Green1, Monica Bhatia2, Erica Y Griffith3, Mahvish Qureshi2, Courtney Briamonte2, Mirko Savone2, Stephen Sands2, Margaret T Lee2, Angela Lignelli4, Adam M Brickman3.   

Abstract

Progressive neurovasculopathy in children with sickle cell disease (SCD) results in decreased cognitive function and quality of life (QoL). Hematopoietic cell transplantation (HCT) is believed to halt progression of neurovasculopathy. Quantitative analysis of T2-weighted fluid attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI) for white matter hyperintensity (WMH) burden provides a meaningful estimate of small vessel cerebrovascular disease. We asked if quantitative analysis of WMH could complement standardized clinical assessment of MRI/magnetic resonance angiography (MRA) for assessing SCD central nervous system vasculopathy before and after HCT. Retrospective longitudinal clinical examination of scheduled annual MRI/MRA and quantitative analysis of WMH were performed before and 1 to 7 years after HCT at scheduled annual intervals, along with QoL measurements, in children who had engrafted after HCT. Of 18 patients alive and persistently engrafted (median age, 9.1 years), pretransplantation MRI demonstrated that 9 and 5 had sickle-related stroke and/or small infarcts, respectively. Patients were divided into WMH severity tertiles based on pretransplantation WMH volumes. MRI and WMH were assessed 1 to 7 years after HCT. MRI/MRA and WMH volume were stable or slightly better in 17 of 18 patients. By parent- and self-report, post-HCT QoL improved for children in the lowest WMH tertile significantly more than in the other groups. Based on this single-institution retrospective sample, we report that WMH appears to quantitatively support MRI-based findings that HCT stabilizes long-term small and large vessel cerebrovascular changes and is associated with the degree of improved QoL. While confirmation in larger prospective studies and evaluation by neurocognitive testing are needed, these findings suggest that WMH is a useful biomarker of neurovasculopathy after transplantation for SCD.
Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hematopoietic cell transplantation; Magnetic resonance imaging brain; Quality of life; Sickle cell disease; White matter hyperintensity

Mesh:

Year:  2017        PMID: 28089760      PMCID: PMC5605134          DOI: 10.1016/j.bbmt.2017.01.007

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  37 in total

1.  Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease.

Authors:  M Bhatia; Z Jin; C Baker; M B Geyer; K Radhakrishnan; E Morris; P Satwani; D George; J Garvin; G Del Toro; W Zuckerman; M T Lee; M Licursi; R Hawks; E Smilow; L A Baxter-Lowe; J Schwartz; M S Cairo
Journal:  Bone Marrow Transplant       Date:  2014-05-05       Impact factor: 5.483

2.  Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel.

Authors:  Emanuele Angelucci; Susanne Matthes-Martin; Donatella Baronciani; Françoise Bernaudin; Sonia Bonanomi; Maria Domenica Cappellini; Jean-Hugues Dalle; Paolo Di Bartolomeo; Cristina Díaz de Heredia; Roswitha Dickerhoff; Claudio Giardini; Eliane Gluckman; Ayad Achmed Hussein; Naynesh Kamani; Milen Minkov; Franco Locatelli; Vanderson Rocha; Petr Sedlacek; Frans Smiers; Isabelle Thuret; Isaac Yaniv; Marina Cavazzana; Christina Peters
Journal:  Haematologica       Date:  2014-05       Impact factor: 9.941

3.  Long-term treatment follow-up of children with sickle cell disease monitored with abnormal transcranial Doppler velocities.

Authors:  Françoise Bernaudin; Suzanne Verlhac; Cécile Arnaud; Annie Kamdem; Isabelle Hau; Emmanuella Leveillé; Manuela Vasile; Florence Kasbi; Fouad Madhi; Christine Fourmaux; Sandra Biscardi; Eliane Gluckman; Gérard Socié; Jean-Hugues Dalle; Ralph Epaud; Corinne Pondarré
Journal:  Blood       Date:  2016-02-05       Impact factor: 22.113

4.  Acute silent cerebral ischemic events in children with sickle cell anemia.

Authors:  Charles T Quinn; Robert C McKinstry; Michael M Dowling; William S Ball; Michael A Kraut; James F Casella; Nomazulu Dlamini; Rebecca N Ichord; Lori C Jordan; Fenella J Kirkham; Michael J Noetzel; E Steve Roach; John J Strouse; Janet L Kwiatkowski; Deborah Hirtz; Michael R DeBaun
Journal:  JAMA Neurol       Date:  2013-01       Impact factor: 18.302

5.  Neurologic complications after allogeneic marrow transplantation for sickle cell anemia.

Authors:  M C Walters; K M Sullivan; F Bernaudin; G Souillet; J P Vannier; F L Johnson; C Lenarsky; D Powars; N Bunin; K Ohene-Frempong
Journal:  Blood       Date:  1995-02-15       Impact factor: 22.113

6.  PedsQL™ Multidimensional Fatigue Scale in sickle cell disease: feasibility, reliability, and validity.

Authors:  Julie A Panepinto; Sylvia Torres; Cristiane B Bendo; Timothy L McCavit; Bogdan Dinu; Sandra Sherman-Bien; Christy Bemrich-Stolz; James W Varni
Journal:  Pediatr Blood Cancer       Date:  2013-09-13       Impact factor: 3.167

7.  The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity.

Authors:  James W Varni; Tasha M Burwinkle; Michael Seid; Douglas Skarr
Journal:  Ambul Pediatr       Date:  2003 Nov-Dec

8.  Reproducibility of detecting silent cerebral infarcts in pediatric sickle cell anemia.

Authors:  Robert I Liem; Jingxia Liu; Mae O Gordon; Bruce A Vendt; Robert C McKinstry; Michael A Kraut; John J Strouse; William S Ball; Michael R DeBaun
Journal:  J Child Neurol       Date:  2013-12-05       Impact factor: 1.987

9.  Volume of white matter hyperintensities is an independent predictor of intelligence quotient and processing speed in children with sickle cell disease.

Authors:  Veronica van der Land; Channa T Hijmans; Marieke de Ruiter; Henri J M M Mutsaerts; Marjon H Cnossen; Marc Engelen; Charles B L M Majoie; Aart J Nederveen; Martha A Grootenhuis; Karin Fijnvandraat
Journal:  Br J Haematol       Date:  2014-10-10       Impact factor: 6.998

Review 10.  Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future.

Authors:  M Bhatia; M C Walters
Journal:  Bone Marrow Transplant       Date:  2007-12-03       Impact factor: 5.483

View more
  4 in total

1.  A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy.

Authors:  Sherif M Badawy; Usman Beg; Robert I Liem; Sonali Chaudhury; Alexis A Thompson
Journal:  Blood Adv       Date:  2021-01-26

Review 2.  Editing outside the body: Ex vivo gene-modification for β-hemoglobinopathy cellular therapy.

Authors:  Tolulope O Rosanwo; Daniel E Bauer
Journal:  Mol Ther       Date:  2021-10-08       Impact factor: 11.454

3.  Hematopoietic stem cell transplantation reverses white matter injury measured by diffusion-tensor imaging (DTI) in sickle cell disease patients.

Authors:  Thalita Cristina de Mello Costa; Rodolfo Chiari-Correia; Carlos Ernesto G Salmon; Luiz Guilherme Darrigo-Junior; Carlos Eduardo S Grecco; Fabiano Pieroni; Joana Teresa B Faria; Ana Beatriz P L Stracieri; Juliana B E Dias; Daniela Aparecida de Moraes; Maria Carolina Oliveira; Renato Guerino-Cunha; Antônio Carlos Santos; Belinda P Simões
Journal:  Bone Marrow Transplant       Date:  2021-07-07       Impact factor: 5.483

4.  Burden of neurological and neurocognitive impairment in pediatric sickle cell anemia in Uganda (BRAIN SAFE): a cross-sectional study.

Authors:  Nancy S Green; Deogratias Munube; Paul Bangirana; Linda Rosset Buluma; Bridget Kebirungi; Robert Opoka; Ezekiel Mupere; Philip Kasirye; Sarah Kiguli; Annet Birabwa; Michael S Kawooya; Samson K Lubowa; Rogers Sekibira; Edwards Kayongo; Heather Hume; Mitchell Elkind; Weixin Peng; Gen Li; Caterina Rosano; Philip LaRussa; Frank J Minja; Amelia Boehme; Richard Idro
Journal:  BMC Pediatr       Date:  2019-10-25       Impact factor: 2.125

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.